TKI-CPK-1003: Prevalence of Creatinine Phosphokinase Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases
Study Details
Study Description
Brief Summary
This study describes the elevation of CPK in patient treated for solid tumors by TKI
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Patient treated by TKI Any patient with solid tumor and treated by Thyrosine Kinase Inhibitor for at least 1 week |
Biological: CPK dosage
CPK dosage during a blood sample realized at least one week after the begining of the treatment
Other: Clinical exam
Examination of the patient for myalgia, cramps, medical history and concomitant medication
|
Outcome Measures
Primary Outcome Measures
- To evaluate the prevalence of the CPK increase [Within 3 days after a clinical exam]
Dosage of CPK during standard blood sampling. The increase of CPK is defined when CPK value > USL
Secondary Outcome Measures
- Correlation myalgia/CPK increase [During the clinical exam]
To determine the correlation between myalgia and CPK blood, taking into account the risk factors leading to CPK increase
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients with solid tumor treated by inhibitor of tyrosin kinase for at least 1 week
-
Patient examined AND with a routine blood test planned
-
Patient informed of procedure for the study who was not opposed to it
Exclusion Criteria:
-
Patient treated for malignant hemopathy
-
Patient no treated by inhibitor of thyrosine kinase or for less than 1 week
-
Patients with no routine blood laboratory tests planned
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Centre Paul Papin | Angers | France | 49000 | |
| 2 | Hôpital Jean Minjoz | Besancon | France | 25030 | |
| 3 | CHU Bordeaux | Bordeaux | France | 33076 | |
| 4 | Institut Bergonié | Bordeaux | France | 33076 | |
| 5 | Centre François Baclesse | Caen | France | 14076 | |
| 6 | Centre Jean Perrin | Clermont Ferrand | France | 63011 | |
| 7 | Hôpital Henri Mondor - APHP | Creteil | France | 94010 | |
| 8 | Centre Oscar Lambret | Lille | France | 59020 | |
| 9 | CHU Limoges | Limoges | France | 87042 | |
| 10 | Hôpital Edouard Herriot | Lyon | France | 69003 | |
| 11 | Centre Léon Bérard | Lyon | France | 69008 | |
| 12 | Institut Paoli Calmettes | Marseille | France | 13273 | |
| 13 | Centre Val d'Aurelle | Montpellier | France | 34298 | |
| 14 | Centre Antoine Lacassagne | Nice | France | 06189 | |
| 15 | Hôpital Saint-Louis - APHP | Paris | France | 75010 | |
| 16 | Hôpital Cochin - APHP | Paris | France | 75014 | |
| 17 | Hôpital Tenon - APHP | Paris | France | 75020 | |
| 18 | Institut Curie | Paris | France | 75248 | |
| 19 | Institut Jean Godinot | Reims | France | 51056 | |
| 20 | CHU Robert Debré | Reims | France | 51092 | |
| 21 | Centre Eugène Marquis | Rennes | France | 35042 | |
| 22 | Centre Henri Becquerel | Rouen | France | 76000 | |
| 23 | Centre René Huguenin | Saint Cloud | France | 92211 | |
| 24 | Institut de Cancérologie de la Loire | Saint Priest en Jarez | France | 42271 | |
| 25 | Institut Claudius Régaud | Toulouse | France | 31052 | |
| 26 | Centre Alexis Vautrin | Vandoeuvre Les Nancy | France | 54511 | |
| 27 | Institut Gustave Roussy | Villejuif | France | 94805 |
Sponsors and Collaborators
- Centre Oscar Lambret
Investigators
- Principal Investigator: Antoine ADENIS, MD, PhD, Centre Oscar Lambret
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- TKI-CPK 1003